Cardioxyl Raises Series B Led By OrbiMed
Cardioxyl Pharmaceuticals has secured $28 million in a Series B financing led by OrbiMed Advisors. New investor Osage University Partners joined OrbiMed and returning investors New Enterprise Associates and The Aurora Funds in the financing.
14 November 2012•3 mins read
